Firefly Neuroscience, Inc. carries no debt; cash flow comfortably covers obligations.

Firefly Neuroscience, Inc.'s free cash flow has decreased 26.67% from $-6.57M last year to $-8.32M, signaling decreasing performance

Firefly Neuroscience, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Firefly Neuroscience, Inc.'s debt has increased relative to shareholder equity from -1.85 last year to 0.00 today, signaling weakened financials

Firefly Neuroscience, Inc. has negative EBITDA, making leverage ratio unreliable

Firefly Neuroscience, Inc. carries no debt; interest obligations are fully covered.

Firefly Neuroscience, Inc.'s profit margin has increased (-94.16%) in the last year from -9.69K% to -565.40%, signaling increasing performance

Firefly Neuroscience, Inc.'s short-term assets of $4.03M exceed its short-term liabilities of $2.82M

Firefly Neuroscience, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Firefly Neuroscience, Inc.'s return on equity of -94.68%, is lower than 15.00%, indicating bad performance

Firefly Neuroscience, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Firefly Neuroscience, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Firefly Neuroscience, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Firefly Neuroscience, Inc. has negative free cash flow, indicating cash burn

Firefly Neuroscience, Inc.'s yearly earnings has decreased 90.08% since last year from $-10.46M to $-19.88M, signaling decreasing performance

Firefly Neuroscience, Inc.'s yearly revenue has increased 957.41% since last year from $108.00K to $1.14M, signaling increasing performance

ROIC -101.11% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Firefly Neuroscience, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Firefly Neuroscience, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Firefly Neuroscience, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Firefly Neuroscience, Inc. has insufficient data to evaluate this check.

Firefly Neuroscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Firefly Neuroscience, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Firefly Neuroscience, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Firefly Neuroscience, Inc. is overvalued relative to its fair value price of -26.29 based on Earnings Fair Value model

Firefly Neuroscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Firefly Neuroscience, Inc. has a price-to-book ratio of 2.15x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Firefly Neuroscience, Inc. has a price-to-sales ratio of 11.48x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue